Ongoing research in this field is focused on identifying subgroups of patients with type 2 diabetes who derive the greatest benefit from GLP-1 RA therapy, using approaches such as pharmacogenomics and investigating non-responders. Here, GLP1R is linked to type 2 diabetes mellitus.